Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New knee implant aims to repair cartilage and avoid repeat surgery

NCT ID NCT07332182

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares a new scaffold implant (MaioRegen Prime) to standard surgical cleaning (debridement) for treating deep cartilage lesions in the knee. About 400 patients aged 18-60 with knee lesions will be randomly assigned to one of the two procedures. The main goal is to see if the implant leads to better knee function and fewer complications or repeat surgeries over two years.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
osteochondral scaffold implant (MaioRegen Prime)
What this could lead to
If successful, this could offer a better surgical option for people with knee cartilage damage, potentially improving function and reducing the need for repeat surgeries.
What could go wrong
This is an early-stage study with no phase designation, and the implant may not prove superior to standard debridement. Risks include surgical complications, implant failure, or no significant benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

May 2026

An estimate. Start dates often move.

Expected to finish

Apr 2031

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Informed consent prior to any study-related procedures; 2. Male or female patients aged between 18 and 60 years (inclusive); 3. Body Mass Index (BMI) ≤ 35; 4. Up to 3 treatable osteochondral lesions localized in femoral condyles and/or trochlea (the patient might have other lesion in other parts of the joint, but they should not be more severe than ICRS Grade II lesions as determined by baseline MRI); 5. Knee osteochondral lesion(s) (Grade IVa and IVb according to ICRS Classification) or not re-fixable knee Osteochondritis Dissecans lesions as determined by baseline MRI; 6. Lesions with an overall treatable area 1-7 cm2 (as determined by baseline MRI). In case of multiple lesions (maximum 3 lesions) in the same knee compartment a minimum distance of 3 mm is required); 7. IKDC Subjective score at baseline (pre-op evaluation) is less than 70; 8. Non-responsive to physical therapy for at least 6 weeks; 9. Patients physically and mentally willing and able to comply with the post-operative rehabilitation protocol and scheduled clinical and radiographic visits. Exclusion Criteria: 1. IKDC subjective score at Baseline is more than or equal to 70; 2. KOOS Pain Subscale score at baseline is less than 20 or more than 65 (scale: maximum pain = 0, pain free = 100); 3. Osteochondral tibial plateau and/or patella defects; 4. Patients affected by advanced osteoarthritis in the index knee (Kellgren and Lawrence classification 3 or 4); 5. Bony defect depth deeper than 5 mm, according to baseline MRI, measured from the original subchondral bone plate level; 6. Uncontained defects: lack of vital bone wall at least 2 mm thick, completely surrounding the lesion - based on MRI; 7. Patients with untreated patellofemoral malalignment or who have undergone realignment procedures within 6 months; 8. Patients with bone fracture or uncorrected malalignment more than 5 degrees varus or valgus according to standing X-ray. 9. Patients previously treated for total or partial meniscectomy in the specific index knee compartments (more than 50% of the meniscus in the index compartments is missing); 10. Patient requiring total or partial meniscectomy to be performed concomitantly, involving more than 50% of one or both menisci in the index knee compartment (lack of functional remaining meniscus, at least 5mm rim at the end of the procedure); and patient requiring ligamentoplasty and high tibial osteotomy (HTO) to be performed concomitantly; 11. Untreated knee ligament instability or treated within 6 months; 12. Kissing (counterposed) osteochondral lesions; 13. Significant instability of the index knee according to IKDC Knee Examination Form 2000: Grade C (abnormal) or D (severely abnormal). 14. Patients affected by any concomitant painful or disabling disease of the spine, hips, or lower limbs, including the contralateral knee, that would interfere with the evaluation of the index knee; 15. Patients affected by bilateral knee lesions that need treatment; 16. Intra-articular steroid injections within 3 months; 17. Any previous cartilage repair procedure (such as: microfracture, Osteochondral autograft transplantation system (OATS), Autologous Matrix Induced Chondrogenesis, (AMIC), Autologous Chondrocyte Implantation (ACI) with or without use of a scaffold (matrix) in the index knee within one year or debridement within 6 months; 18. Patients affected by osteoporosis (established through x-ray tests, called DEXA scans, bone density, etc. Criteria for osteoporosis: T-score is \< - 2.5 SD), chondrodysplasia, or osteogenesis imperfecta; 19. Patients affected by known allergy to equine collagen or calcium-phosphates; 20. Patients who underwent chemotherapy in the past 12 months; 21. Patients with a known history of any significant systemic disease (such as but not limited to: HIV, hepatitis, HTLV, syphilis, coagulopathies, insulin dependent diabetes mellitus etc.) or affected by a significant malignancy; 22. Participation in other clinical trials within 90 days prior to the study or concurrent with the study; 23. Patient who is pregnant (or intends to become pregnant within one-year post-op) or breastfeeding; 24. Known drugs or alcohol abuse; 25. Any evidence of active infection anywhere in the body. Urinary Tract Infection (UTI) patients can be included following antibiotic treatment, and provided that two consecutive cultures are negative (taken within at least 2 weeks of each other); 26. Any known history of intra-articular or osseous infection of the index knee; 27. Patients affected by a known history of inflammatory arthropathy or crystal-deposition arthropathy; 28. Prisoners; 29. The existence of any surgical or medical condition that, in the judgement of the Investigator, might compromise patient safety or the outcome of the study; 30. Any medical conditions or implants that would prevent the participant from undergoing an MRI, including but not limited to pacemakers, clips, cochlear implants, or metal shrapnel.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Early osteoarthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.